Startup
Melbourne, VIC
Every investor coverage indicates participated in a round Tessara Therapeutics Pty Ltd raised.
| Investor | Rounds | Invested |
|---|---|---|
| Jumar Bioincubator | Accelerator | - |
| Tech23 | Accelerator | - |
Companies Tessara Therapeutics Pty Ltd acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Christopher Boyer | Director and Head of Corporate and Strategic Development | Wholesale Investor |
| Christopher Boyer | Director | Wholesale Investor |
| Dr Christian Toouli | Chief Commercial Officer | Wholesale Investor |
| Dr Christos Papadimitriou | CEO | Startup Daily, Wholesale Investor (Thu 28 May 2020), Wholesale Investor (Thu 5 Mar 2020) |
| Dr Greg Collier | Independent Chairman | Wholesale Investor (Thu 28 May 2020), Wholesale Investor (Thu 5 Mar 2020) |
| Phillip Smith | Director | Wholesale Investor |
Stories naming Tessara Therapeutics Pty Ltd. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eight university- and company-led Australian quantum projects share $12.7 million in stage-two Critical Technologies Challenge Program grants, funding prototypes for data-centre cooling, medical imaging and rare-earth detection.
A profile of six life-science ventures that graduated from Melbourne bioincubator Jumar's debut program, one of which, Tessara Therapeutics, won a $3 million research grant in December.
Startup Daily TV interviews Tessara Therapeutics' CEO about RealBrain, its 3D brain-tissue models for neurological drug discovery, and a fresh push to raise funds; the Melbourne biotech is also among the latest Tech23 companies.
Tessara Therapeutics closed a $2.7 million oversubscribed Round 1 raise led by a New South Wales syndicate, appointed Phillip Smith to its board, and works with CSIRO and Bio-Link Australia.
Wholesale Investor profile of Tessara Therapeutics, a biotech developing 3D human brain tissue for drug discovery; recounts past grants, an R&D tax incentive, CSIRO partnership, board and revenue projections.